INT47944

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 1994
Last Reported 2009
Negated 1
Speculated 0
Reported most in Abstract
Documents 23
Total Number 23
Disease Relevance 0.16
Pain Relevance 6.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Glp1r) signal transducer activity (Glp1r)
Anatomy Link Frequency
FRIC 4
ileum 4
fat 4
gut 4
colon 2
Glp1r (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Somatostatin 25 100.00 Very High Very High Very High
qutenza 15 100.00 Very High Very High Very High
agonist 36 99.96 Very High Very High Very High
substance P 18 99.76 Very High Very High Very High
tetrodotoxin 5 99.60 Very High Very High Very High
antagonist 34 99.58 Very High Very High Very High
Neurotransmitter 16 99.30 Very High Very High Very High
Calcitonin gene-related peptide 5 97.92 Very High Very High Very High
Cholecystokinin 3 96.16 Very High Very High Very High
Dopamine 3 94.88 High High
Disease Link Frequency Relevance Heat
Impaired Glucose Tolerance 18 80.96 Quite High
Diabetes Mellitus 4 75.12 Quite High
Aids-related Complex 53 41.68 Quite Low
Stress 2 22.48 Low Low
Hyperinsulinism 3 5.00 Very Low Very Low Very Low
Hyperglycemia 3 5.00 Very Low Very Low Very Low
Appetite Loss 3 5.00 Very Low Very Low Very Low
Rheumatoid Arthritis 2 5.00 Very Low Very Low Very Low
Sprains And Strains 1 5.00 Very Low Very Low Very Low
Targeted Disruption 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It enhanced GLP-1 release up to sixfold above basal during the early phase followed by a sustained secretion at 400% above basal.
Positive_regulation (enhanced) of Localization (release) of GLP-1
1) Confidence 0.70 Published 1995 Journal J. Endocrinol. Section Abstract Doc Link 7490533 Disease Relevance 0 Pain Relevance 0.33
Arterial infusion of cholinergic agonists strongly enhanced GLP-1 secretion which was counteracted by the addition of atropine.
Positive_regulation (enhanced) of Localization (secretion) of GLP-1 associated with agonist
2) Confidence 0.70 Published 1995 Journal J. Endocrinol. Section Abstract Doc Link 7490533 Disease Relevance 0 Pain Relevance 0.34
Atropine (a nonspecific muscarinic receptor antagonist) completely inhibited fat-induced GLP-1 secretion in vivo (P < 0.01).
Positive_regulation (induced) of Localization (secretion) of GLP-1 in fat associated with antagonist
3) Confidence 0.69 Published 2002 Journal Endocrinology Section Abstract Doc Link 12021207 Disease Relevance 0 Pain Relevance 0.26
Pirenzepine (an M1 muscarinic receptor antagonist) also inhibited fat-induced GLP-1 secretion in vivo, by 91 +/- 6% (P < 0.01).
Positive_regulation (induced) of Localization (secretion) of GLP-1 in fat associated with antagonist
4) Confidence 0.69 Published 2002 Journal Endocrinology Section Abstract Doc Link 12021207 Disease Relevance 0 Pain Relevance 0.27
Incubating FRIC cultures with bethanechol (a muscarinic receptor agonist) stimulated GLP-1 secretion to 200 +/- 22% of control (P < 0.01).
Positive_regulation (stimulated) of Localization (secretion) of GLP-1 in FRIC associated with agonist
5) Confidence 0.69 Published 2002 Journal Endocrinology Section Abstract Doc Link 12021207 Disease Relevance 0 Pain Relevance 0.26
To test the possibility that hormones produced by the proximal small intestine or transmitters of the enteric nervous system may be involved in the early phase of meal-induced GLP-1 secretion, various intestinal regulatory peptides and neurotransmitters of the gut were administered intraarterially in the isolated vascularly perfused rat colon preparation.
Positive_regulation (induced) of Localization (secretion) of GLP-1 in colon associated with neurotransmitter
6) Confidence 0.69 Published 1994 Journal Endocrinology Section Abstract Doc Link 7988423 Disease Relevance 0 Pain Relevance 0.18
Bombesin (10(-9)-10(-7) M) provoked a dose-dependent release of GLP-1, consisting of an early peak, followed by a sustained response.
Positive_regulation (followed) of Localization (release) of GLP-1
7) Confidence 0.69 Published 1994 Journal Endocrinology Section Abstract Doc Link 7988423 Disease Relevance 0 Pain Relevance 0.34
Unexpectedly, 4-diphenylacetoxy-N-methylpiperidine stimulated GLP-1 secretion by FRIC cells, to 324 +/- 52% of the control value (P < 0.01).
Positive_regulation (stimulated) of Localization (secretion) of GLP-1 in FRIC
8) Confidence 0.61 Published 2002 Journal Endocrinology Section Abstract Doc Link 12021207 Disease Relevance 0 Pain Relevance 0.23
Pirenzepine and gallamine significantly inhibited bethanechol-stimulated GLP-1 secretion, by 96 +/- 12% and 98 +/- 8%, respectively (P < 0.01).
Positive_regulation (bethanechol-stimulated) of Localization (secretion) of GLP-1
9) Confidence 0.50 Published 2002 Journal Endocrinology Section Abstract Doc Link 12021207 Disease Relevance 0 Pain Relevance 0.25
General stimulation of adrenergic receptors with epinephrine (10(-7) M) induced significant GLP-1 and PYY secretions (94+/-38 and 257+/-59 fmol/8 min respectively) which were abolished upon propranolol (10(-7) M) pretreatment and strongly decreased upon infusion with 10(-8) M prazosin.
Positive_regulation (induced) of Localization (secretions) of GLP-1
10) Confidence 0.49 Published 1999 Journal J. Endocrinol. Section Abstract Doc Link 10425466 Disease Relevance 0 Pain Relevance 0.12
The beta-adrenergic agonist isoproterenol (10(-6) M) infused for 30 min induced a transient release of GLP-1 and PYY (integrated release over the 8 min of the peak secretion: 38+/-16 and 214+/-69 fmol for GLP-1 and PYY respectively, P<0.05).
Positive_regulation (induced) of Localization (release) of GLP-1 associated with agonist
11) Confidence 0.49 Published 1999 Journal J. Endocrinol. Section Abstract Doc Link 10425466 Disease Relevance 0 Pain Relevance 0.16
Because terbutaline but not dobutamine or BRL 37,344 (10(-5) M) induced significant GLP-1 and PYY secretions (135+/-30 and 305+/-39 fmol/8 min respectively), isoproterenol-induced secretions are suggested to result mainly from stimulation of the beta2-isoreceptor type.
Neg (not) Positive_regulation (induced) of Localization (secretions) of GLP-1
12) Confidence 0.49 Published 1999 Journal J. Endocrinol. Section Abstract Doc Link 10425466 Disease Relevance 0 Pain Relevance 0.24
The beta-adrenergic agonist isoproterenol (10(-6) M) infused for 30 min induced a transient release of GLP-1 and PYY (integrated release over the 8 min of the peak secretion: 38+/-16 and 214+/-69 fmol for GLP-1 and PYY respectively, P<0.05).
Positive_regulation (integrated) of Localization (release) of GLP-1 associated with agonist
13) Confidence 0.49 Published 1999 Journal J. Endocrinol. Section Abstract Doc Link 10425466 Disease Relevance 0 Pain Relevance 0.16
Tetrodotoxin did not modify the bombesin-induced release of PYY, GLP-1, and NT.
Positive_regulation (bombesin-induced) of Localization (release) of GLP-1 associated with tetrodotoxin
14) Confidence 0.48 Published 1995 Journal Endocrinology Section Abstract Doc Link 7588257 Disease Relevance 0 Pain Relevance 0.31
Peptides and neurotransmitters thought to be candidate mediators triggering GLP-1 secretion were arterially infused and GLP-1 was measured in the venous effluent.
Positive_regulation (triggering) of Localization (secretion) of GLP-1 associated with neurotransmitter
15) Confidence 0.47 Published 1995 Journal J. Endocrinol. Section Abstract Doc Link 7490533 Disease Relevance 0 Pain Relevance 0.31
GLP-1 secretion from the distal gut increased 5-fold after 3 ml corn oil were placed into the proximal duodenum (P < 0.001).
Positive_regulation (increased) of Localization (secretion) of GLP-1 in gut
16) Confidence 0.47 Published 2002 Journal Endocrinology Section Abstract Doc Link 12021207 Disease Relevance 0 Pain Relevance 0.23
The mechanism by which dietary peptides stimulate GLP-1 secretion in the gut is unknown.
Positive_regulation (stimulate) of Localization (secretion) of GLP-1 in gut
17) Confidence 0.46 Published 2009 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 19661152 Disease Relevance 0 Pain Relevance 0.07
In the present study, we found that a hydrolysate prepared from zein, a major corn protein [zein hydrolysate (ZeinH)], strongly stimulates GLP-1 secretion in enteroendocrine GLUTag cells.
Positive_regulation (stimulates) of Localization (secretion) of GLP-1
18) Confidence 0.46 Published 2009 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 19661152 Disease Relevance 0 Pain Relevance 0.15
GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats.
Positive_regulation (enhanced) of Localization (secretion) of GLP-1 in ileum associated with qutenza
19) Confidence 0.46 Published 2009 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Title Doc Link 19661152 Disease Relevance 0 Pain Relevance 0.23
GLP-1 augments nutrient-induced insulin release (1,2), inhibits glucagon release (3), slows gastric emptying (4), and has islet-independent effects to reduce hepatic glucose production (5–8).
Positive_regulation (induced) of Localization (release) of GLP-1
20) Confidence 0.44 Published 2008 Journal Diabetes Section Body Doc Link PMC2494674 Disease Relevance 0.16 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox